[go: up one dir, main page]

AR100289A1 - FORMS OF A PI3K INHIBITOR - Google Patents

FORMS OF A PI3K INHIBITOR

Info

Publication number
AR100289A1
AR100289A1 ARP150101368A ARP150101368A AR100289A1 AR 100289 A1 AR100289 A1 AR 100289A1 AR P150101368 A ARP150101368 A AR P150101368A AR P150101368 A ARP150101368 A AR P150101368A AR 100289 A1 AR100289 A1 AR 100289A1
Authority
AR
Argentina
Prior art keywords
forms
pi3k inhibitor
purin
quinolinyl
pyridinyl
Prior art date
Application number
ARP150101368A
Other languages
Spanish (es)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR100289A1 publication Critical patent/AR100289A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan formas de hidrato y anhidrato de N-((1S)-1-(7-flúor-2-(2-piridinil)-3-quinolinil)etil)-9H-purin-6-amina. Se proporcionan además composiciones farmacéuticas que contienen las formas, y métodos para el uso de dichas composiciones para el tratamiento del cáncer.N - ((1S) -1- (7-fluorine-2- (2-pyridinyl) -3-quinolinyl) ethyl) -9H-purin-6-amine hydrate and anhydrate forms are provided. Pharmaceutical compositions containing the forms, and methods for the use of said compositions for the treatment of cancer are also provided.

ARP150101368A 2014-05-06 2015-05-06 FORMS OF A PI3K INHIBITOR AR100289A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989383P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
AR100289A1 true AR100289A1 (en) 2016-09-21

Family

ID=53190052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101368A AR100289A1 (en) 2014-05-06 2015-05-06 FORMS OF A PI3K INHIBITOR

Country Status (3)

Country Link
AR (1) AR100289A1 (en)
TW (1) TW201625621A (en)
WO (1) WO2015171725A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
CN117916235A (en) * 2021-08-11 2024-04-19 泰州亿腾景昂药业股份有限公司 Cyclin-dependent kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2137186T3 (en) 2007-03-23 2016-09-30 Heterocyclic compounds and their uses
PE20142457A1 (en) 2012-04-04 2015-02-07 Amgen Inc HETEROCICLIC COMPOUNDS AND THEIR USES

Also Published As

Publication number Publication date
TW201625621A (en) 2016-07-16
WO2015171725A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
MX2016013457A (en) MDM2 INHIBITORS AND THERAPEUTIC METHODS THAT USE THE SAME.
CL2016002027A1 (en) Cyclopropylamine as an inhibitor of lsd1
MX2023007841A (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy.
CL2018001230A1 (en) Osteoarthritis treatment
CL2016003422A1 (en) Lysine specific demethylase-1 inhibitors
CL2015002932A1 (en) Protein kinase inhibitors
MX373318B (en) 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE-FOR USE IN THE TREATMENT OF CANCER.
MX2016002137A (en) CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS.
CL2016000807A1 (en) Amino heteroaryl benzamides as kinase inhibitors.
EA201891024A1 (en) TANK-BINDING KINASE INHIBITOR COMPOUNDS
ECSP17016797A (en) INDAZOLES SUBSTITUTED WITH BENZYL AS BUB1 INHIBITORS
CL2016003423A1 (en) Lysine specific demethylase-1 inhibitors
CL2016002495A1 (en) Macrocyclic pyridine derivatives.
MX2016012097A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
MX381487B (en) CERTAIN PROTEIN KINASE INHIBITORS.
CL2015001985A1 (en) Thiazolcarboxamides and pyridinecarboxamide compounds, pim kinase inhibitors.
MX2016015743A (en) Cyclopropylamine compounds as histone demethylase inhibitors.
CL2015002628A1 (en) Heteroaryl compounds and their uses.
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
UY36175A (en) 3-AMINO-1,5,6,7-TETRAHIDRO-4H-INDOL-4-ONAS
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
CL2016003214A1 (en) Indolizine derivatives as phosphoinositide-3 kinase inhibitors
MX2016009590A (en) APILIMOD COMPOSITIONS AND METHODS TO USE THE SAME.
BR112017000730B8 (en) PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS, AND DRUGS
MX395032B (en) CERTAIN PROTEIN KINASE INHIBITORS.

Legal Events

Date Code Title Description
FB Suspension of granting procedure